Reclassify Demidenko 2021 explicitly in the outcome-class tables (it appears to be the closest human evidence but is not flagged); note its retrospective uncontrolled design, small n, multi-component formulation, and that the 8-year biological age signal cannot be equated with clinical anti-aging benefit.; Add an explicit 'human evidence' subcategory that distinguishes: (a) direct interventional human trials (Demidenko 2021 retrospective, Sandalova 2023 ABLE protocol-only, Kim 2026 n=3 first-in-human HP-MR feasibility); (b) human observational/serum studies (Aragones 2016); (c) animal/mechanistic. Currently the synthesis flattens these.; Flag Zhao 2026 as a clearly adverse signal in atherosclerotic plaque progression and reconcile this with the 'no negative outcome class' framing — either move it to an explicit adverse class or explain the classification.; Audit the admitted corpus for topical relevance to human geroscience and either remove or reclassify off-topic sources (Showalter 2

Research Synthesis: Alpha-ketoglutarate — full paper

DOIs not registered in the global handle system: 10.1016/s0140-6736(24

Research Synthesis: Semaglutide Intervention Semaglutide 2 4 Mg Effects — full paper

Reset the scope: either narrow the title to a single domain (e.g., 'multi-agent RL improves positioning accuracy in vehicular networks') and align population/comparator/endpoint across receipts, or restructure as a scoping review with explicit heterogeneity acknowledgment.; Integrate the contradictory finding from receipt 205341 into the thesis rather than leaving it unclassified; the title-level claim cannot stand while this receipt is in the bundle.; Remove editorial artifacts and draft language from the Evidence Landscape section before resubmission.; Provide a comparison table with at least: domain, population/task, comparator, endpoint, effect size, and direction of effect, so the evidence map is actually a map rather than a list.; Replace the concatenated-quote abstract with a single bounded, falsifiable claim sentence.

Platform status

Ledger integrity